The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInt Diag Hld Regulatory News (IDHC)

Share Price Information for Int Diag Hld (IDHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.32
Bid: 0.31
Ask: 0.321
Change: -0.029 (-8.42%)
Spread: 0.011 (3.548%)
Open: 0.34
High: 0.34
Low: 0.32
Prev. Close: 0.3445
IDHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

CFO & Strategic Investment Officer Appointments

21 Jun 2023 11:18

RNS Number : 4666D
Integrated Diagnostics Holdings PLC
21 June 2023
 

IDH appoints new Chief Financial Officer and Strategic Investment Officer

21 June 2023

(Cairo and London) - Integrated Diagnostics Holdings ("IDH," "the Group," or "the Company"), a leading provider of diagnostics services with operations in Egypt, Jordan, Nigeria and Sudan, announces the appointment of Ahmed El Gebeily as Group Chief Financial Officer, effective 15 August 2023. His appointment will follow the departure of IDH's long-term VP Finance and Strategies and Group Chief Financial Officer, Omar Bedewy, on 30 June 2023. Bedewy has been with IDH since 2016 and has played a vital role in the Company's growth and expansion in recent years. IDH is also excited to announce the appointment of Sherif El Etreby, who will fill the role of Group Strategic Investment Officer, effective 15 August 2023.

During the transition, Bedewy, along with the rest of IDH's management team, is committed to ensuring an efficient handover of responsibilities, remaining diligent in the Company's transitional phase until El Gebeily effectively assumes his role as Group Chief Financial Officer. Following Bedewy's departure, Ahmed Sileem will fill the position of Interim Chief Financial Officer until El Gebeily fills the role on 15 August 2023. Sileem currently serves as Regional Financial Controller at IDH and has been with the Company since 2012.

El Etreby, filling the new role of Group Strategic Investment Officer, will be responsible for developing and directing the Group's strategy pillars and long-term outlook, identifying potential opportunities for business expansion. This new position was created in line with IDH's continuous efforts to identify and maximise long-term growth across its current and potential markets.

Dr. Hend El Sherbini, Group Chief Executive Officer, commented: "On behalf of IDH's Board of Directors and management team, I would like to thank Omar for his invaluable contributions to the Company over the past seven years, and his pivotal role in our growth story. Omar has been an exceptional leader within IDH's walls since he first joined in 2016 and has helped navigate the Company through some of its most challenging times. We wish him all the best in his future endeavours.

"In the coming weeks, and along with the rest of the management team, I will prioritize the smooth continuation of all our business operations, as well as safeguard an effective handover to our next CFO, who will surely continue to play as pivotal a role as Omar has in the past years. I am excited at the level of experience that both additions to our management team bring with them. Both Ahmed and Sherif are experienced executives with unique skills and expertise, and I have the utmost confidence in their ability to further guide IDH in its future growth plans and their ability to lead within the IDH family. The addition of the Strategic Investment Officer role to our team marks a new era for IDH, and further reaffirms our commitment to delivering strategic growth wherever possible." Dr. Hend added.

Commenting on his departure, Omar Bedewy, Chief Financial Officer, said: "I am truly grateful for the incredible journey I have had during my tenure at IDH. It has been an absolute privilege working alongside a talented and dedicated team throughout the years. Together, we have accomplished remarkable milestones that have cemented our position as a leading healthcare provider in all our markets. Over the coming weeks, I remain committed to seeing the full handover of my roles and responsibilities to my successor to ensure continued success for IDH under his guidance.

"As I move on from my role, I want to express my heartfelt wishes for IDH's continued success and future growth. I have the utmost confidence in the organization's ability to navigate the evolving healthcare landscape and continue to make great strides in the future. I will continue to follow IDH's progress and celebrate its achievements with immense pride as it continues touching lives and remaining on the front lines providing quality healthcare in the region." He added.

Ahmed El Gebeily Bio

El Gebeily is a senior executive finance director with nearly three decades of experience and a successful track record in business start-ups in various international and local settings, including construction, building material industries, among others. He currently serves as the Chief Financial Officer at Egyptian Industrial Investment Group.

His previous experiences include Senior Executive Finance Director at Egyptian Steel Group, Regional Finance Director at Lafarge Middle East and Africa, and Head of Finance for New Projects at Orascom Industries - Cement Division. Prior to these roles, El Gebeily held several positions with Kharafi Group, where he was stationed in several countries, including Albania, Syria, South Africa and Mozambique.

He boasts a unique set of skills and experience, including experience in company management, holding restructuring and liquidation, designing accounting systems, ERP implementation, and company registration processes.

During his tenure, he gained strong exposure in acquisitions, due diligence, post-purchase audits, joint venture management, sale and purchase agreements (SPA), shareholders loan agreements, as well as the management and setup of full Financial Shared Services Centre (FSSC), both locally and regionally.

El Gebeily's skills also include project financial management, costing and contract negotiation, and closure. He is an expert with internal control functions, budget monitoring, and performance analysis, as well as corrective measure implementation. He has strong experience in tax optimisation, tax disputes, and tax refunds in several countries. Finally, El Gebeily is skilled at knowledge transferring, team building, and training future generations for leadership positions.

Sherif El Etreby Bio

El Etreby is a seasoned financial executive with over 25 years of experience in the financial field, boasting several significant roles and major achievements in banking institutions for 10 years. He currently serves as the Senior Vice President of Investments at Egyptian Industrial Investment Group.

El Etreby's previous experiences include nine years as the Senior Planning Executive at Egyptian Steel Group, as well as a member of the founding team of Egyptian Cement Company during the same period. Prior to those roles, he served as the Regional Controller for Special Projects - Middle East and Africa at Lafarge, as well as Deputy Regional Business Controller for North Africa and Head of Planning at Orascom Construction - Cement Sector.

He has been involved in major syndication loans facilities, acquisitions, and divestments in the cement and steel sectors in the Middle East and Africa, including the acquisition of Lafarge to Orascom Construction Industries - Cement Sector in 2008. He was also involved in the sell down of the founder's stack in Egyptian Steel Group to Al Ezz Dekheila Steel Co. in 2021.

 

-Ends-

 

About Integrated Diagnostics Holdings (IDH)

IDH is a leading diagnostics services provider in the Middle East and Africa offering a broad range of pathology and radiology tests to patients in Egypt, Jordan, Nigeria and Sudan. The Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and Echo-Lab (Nigeria). A long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 2,000 diagnostics tests. From its base of 552 branches as of 31 December 2022, IDH served over 8.7 million patients and performs more than 32.7 million tests in 2022. IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group's expansion plans include acquisitions in new Middle Eastern, African, and East Asian markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a Standard Listing on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015 with a secondary listing on the EGX since May 2021 (ticker: IDHC.CA).

Learn more at idhcorp.com.

 

Contact

Nancy Fahmy

Investor Relations Director

T: +20 (0)2 3345 5530 | M: +20 (0)12 2255 7445 | nancy.fahmy@idhcorp.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAPPUAGQUPWGUG
Date   Source Headline
4th Apr 20241:55 pmRNSAnnual Financial Report
28th Mar 20247:00 amRNSFinal Results
26th Mar 20249:15 amRNSNotice of Results
18th Jan 20244:03 pmRNSIDH appoints Group CFO, VP and Board Member
16th Nov 20237:00 amRNS3rd Quarter Results
25th Oct 20237:00 amRNSIDH CEO increases stake in the Company
17th Oct 20231:56 pmRNSDirector/PDMR Shareholding
16th Oct 202312:26 pmRNSDirector/PDMR Shareholding
13th Oct 20232:02 pmRNSDirector/PDMR Shareholding
12th Oct 202310:33 amRNSDirector/PDMR Shareholding
11th Oct 202310:45 amRNSDirector/PDMR Shareholding
31st Aug 20237:00 amRNSHalf-year Report
30th Aug 20239:57 amRNSNotice of Results
21st Jun 202311:18 amRNSCFO & Strategic Investment Officer Appointments
14th Jun 20233:01 pmRNSDirector/PDMR Shareholding
1st Jun 20237:00 amRNS1st Quarter Results
30th May 20235:49 pmRNSResult of AGM
4th May 20233:03 pmRNSAnnual Financial Report & Notice of AGM
28th Apr 20234:01 pmRNSDirector/PDMR Shareholding
18th Apr 20233:23 pmRNSDirector/PDMR Shareholding
6th Apr 202311:05 amRNSFinal Results
6th Apr 20237:00 amRNSPreliminary Results
4th Apr 20236:10 pmRNSNotice of Results
21st Feb 20234:35 pmRNSPrice Monitoring Extension
6th Feb 20234:40 pmRNSSecond Price Monitoring Extn
6th Feb 20234:35 pmRNSPrice Monitoring Extension
31st Jan 20237:00 amRNSIDH to no longer pursue acquisition of IDC stake
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
17th Nov 20227:00 amRNS3rd Quarter Results
10th Nov 20221:55 pmRNSNotice of Results
31st Oct 202210:06 amRNSIDH launches Greenfield in KSA with Izhoor
5th Oct 20221:09 pmRNSIDH launches sixth Al-Borg Scan Branch
5th Oct 202212:49 pmRNSAl-Borg Scan obtains ACR Accreditation
12th Sep 20228:23 amRNSHalf-year Report
7th Sep 20224:04 pmRNSNotice of Results
6th Sep 20229:30 amRNSIDC termination; negotiations ongoing
22nd Aug 20224:40 pmRNSSecond Price Monitoring Extn
22nd Aug 20224:36 pmRNSPrice Monitoring Extension
17th Aug 20224:41 pmRNSSecond Price Monitoring Extn
17th Aug 20224:36 pmRNSPrice Monitoring Extension
16th Aug 20222:09 pmRNSIDH CEO ups stake in the Company
16th Aug 202211:19 amRNSDirector/PDMR Shareholding
15th Aug 20224:41 pmRNSSecond Price Monitoring Extn
15th Aug 20224:36 pmRNSPrice Monitoring Extension
11th Aug 20226:01 pmRNSDirector/PDMR Shareholding
11th Aug 20225:44 pmRNSDirector/PDMR Shareholding
9th Aug 20225:27 pmRNSDirector/PDMR Shareholding
9th Aug 20222:50 pmRNSDirector/PDMR Shareholding
5th Aug 20223:27 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.